Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Bial R&D Investments, S.A.
Study ID
NCT07522606
Status
No Longer Available

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • BIA 28-6156 — DRUG
    60mg dosage of BIA 28-6156 taken orally once daily

Study Details

This Program is designed to provide continued access BIA 28-6156, free and compassionately for an eligible patient previously enrolled in the BIA 28-6156-201 (ACTIVATE) clinical study and that had completed the study.

Key Dates

First listed
Apr 13, 2026
Status verified
Aug 2026

Locations (16)

FacilityCityStateZIPSite coordinators
Barrow Neurological InstitutePhoenixArizona85013-
University of ColoradoAuroraColorado80045-
Parkinson's Center and Movement Disorders of Boca RatonBoca RatonFlorida33486-
University of Miami, Dept. of NeurologyMiamiFlorida33136-
Northwestern UniversityChicagoIllinois60611-
University of Kansas Medical CenterKansas CityKansas66103-
University of KentuckyLexingtonKentucky40536-
University of Maryland Medical CenterBaltimoreMaryland21201-
Massachusetts General HospitalBostonMassachusetts02114-
Park Nicollet Struther's Parkinson's Center (Struthers Parkinsons Center at HealthPartners)Saint PaulMinnesota55427-
Cleveland Clinic FoundationClevelandOhio44195-
MUSCCharlestonSouth Carolina29425-
Vanderbilt Medical CenterNashvilleTennessee37232-
Intermountain HealthcareSalt Lake CityUtah84107-
University of WashingtonSeattleWashington98195-
Inland Northwest ResearchSpokaneWashington99202-

Find similar trials in Phoenix, AZ

Related Studies